Journal of Autism and Developmental Disorders

, Volume 47, Issue 11, pp 3489–3496 | Cite as

Interactive Effects of Prenatal Antidepressant Exposure and Likely Gene Disrupting Mutations on the Severity of Autism Spectrum Disorder

  • Sean Ackerman
  • Sarah Schoenbrun
  • Caitlin Hudac
  • Raphael Bernier
Original Paper

Abstract

To examine the interactive effects of two proposed risk factors which may contribute to symptom severity of Autism Spectrum Disorder (ASD): prenatal antidepressant exposure and likely gene-disrupting (LGD) mutations. Participants included 2748 individuals with ASD from the Simons Simplex Collection. We examined the effects of prenatal antidepressant exposure, maternal depression, presence of an LGD mutation and their interaction on ASD severity. We found a significant interactive effect between antidepressant exposure and the presence of an LGD mutation on ASD severity in the ADOS and ADI-R verbal communication domains. We consider a “two-hit” model in which one variable lays the foundation for an initial risk which is compounded by a second variable.

Keywords

Autism ASD Antidepressants SSRI Genetics 

References

  1. American Psychiatric Association (2013). Diagnostic and statistical manual of mental disorders (5th edn.). Arlington, VA: American Psychiatric Publishing.CrossRefGoogle Scholar
  2. Atladóttir HÓ, Henriksen, T. B., Schendel, D. E., et al. (2012). Autism after infection, febrile episodes, and antibiotic use during pregnancy: An exploratory study. Pediatrics, 130(6), e1447–e1454.CrossRefPubMedPubMedCentralGoogle Scholar
  3. Boukhris, T., Sheehy, O., Mottron, L., et al. (2015). Antidepressant use during pregnancy and the risk of autism spectrum disorder in children. JAMA Pediatrics, 170(2), 117–124.CrossRefGoogle Scholar
  4. Chaste, P., & Leboyer, M. (2012). Autism risk factors: Genes, environment, and gene-environment interactions. Dialogues in Clinical Neuroscience, 14(3), 281–292.PubMedPubMedCentralGoogle Scholar
  5. Cooper, W. O., Willy, M. E., Pont, S. J., & Ray, W. A. (2007). Increasing use of antidepressants in pregnancy. American Journal of Obstetrics and Gynecology, 196(6), 544.e1-5.CrossRefPubMedGoogle Scholar
  6. Croen, L. A., Grether, J. K., Yoshida, C. K., et al. (2011). Antidepressant use during pregnancy and childhood autism spectrum disorders. Archives of General Psychiatry, 68(11), 1104–1112.CrossRefPubMedGoogle Scholar
  7. Fischbach, G. D., & Lord, C. (2010). The Simons Simplex Collection: A resource for identification of autism genetic risk factors. Neuron, 68(2), 192–195.CrossRefPubMedGoogle Scholar
  8. Gardener, H., Spiegelman, D., & Buka, S. L. (2009). Prenatal risk factors for autism: Comprehensive meta-analysis. The British Journal of Psychiatry, 195(1), 7–14.CrossRefPubMedPubMedCentralGoogle Scholar
  9. Gentile, S. (2015). Prenatal antidepressant exposure and the risk of autism spectrum disorders in children. Are we looking at the fall of Gods? Journal of Affective Disorders, 182, 132–137.CrossRefPubMedGoogle Scholar
  10. Gidaya, N. B., Lee, B. K., Burstyn, I., et al. (2014). In utero exposure to selective serotonin reuptake inhibitors and risk for autism spectrum disorder. Journal of Autism and Developmental Disorders, 44(10), 2558–2567.CrossRefPubMedGoogle Scholar
  11. Girirajan, S., Dennis, M. Y., Baker, C., et al. (2013). Refinement and discovery of new hotspots of copy-number variation associated with autism spectrum disorder. American Journal of Human Genetics, 92(2), 221–237.CrossRefPubMedPubMedCentralGoogle Scholar
  12. Girirajan, S., & Eichler, E. E. (2010). Phenotypic variability and genetic susceptibility to genomic disorders. Human Molecular Genetics, 19(R2), R176–R187.CrossRefPubMedPubMedCentralGoogle Scholar
  13. Girirajan, S., Rosenfeld, J. A., Coe, B. P., et al. (2012). Phenotypic heterogeneity of genomic disorders and rare copy-number variants. The New England Journal of Medicine, 367(14), 1321–1331.CrossRefPubMedPubMedCentralGoogle Scholar
  14. Girirajan, S., Rosenfeld, J. A., Cooper, G. M., Antonacci, F., et al. (2010). A recurrent 16p12.1 microdeletion supports a two-hit model for severe developmental delay. Nature Genetics, 42, 203–209.CrossRefPubMedPubMedCentralGoogle Scholar
  15. Gotham, K., Pickles, A., & Lord, C. (2009). Standardizing ADOS scores for a measure of severity in autism spectrum disorders. Journal of Autism and Developmental Disorders, 39(5), 693–705.CrossRefPubMedGoogle Scholar
  16. Hanson, E., Bernier, R., Porche, K., et al. (2015). Simons Variation in Individuals Project Consortium. The cognitive and behavioral phenotype of the 16p11.2 deletion in a clinically ascertained population. Biological Psychiatry, 77(9), 785–793.CrossRefPubMedGoogle Scholar
  17. Harrington, R. A., Lee, L. C., Crum, R. M., et al. (2014). Prenatal SSRI use and offspring with autism spectrum disorder or developmental delay. Pediatrics 133(5), 1241–1248.CrossRefGoogle Scholar
  18. Hus, V., Gotham, K., & Lord, C. (2014). Standardizing ADOS domain scores: Separating severity of social affect and restricted and repetitive behaviors. Journal of Autism and Developmental Disorders, 44(10), 2400–2412.CrossRefPubMedPubMedCentralGoogle Scholar
  19. Hviid, A., Melbye, M., & Pasternak, B. (2013). Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism. The New England Journal of Medicine, 369(25), 2406–2415.CrossRefPubMedGoogle Scholar
  20. Iossifov I, O’Roak BJ, Sanders SJ, et al. (2014). The contribution of de novo coding mutations to autism spectrum disorder. Nature 515(7526):216–221.CrossRefPubMedPubMedCentralGoogle Scholar
  21. Kalkbrenner, A. E., Windham, G. C., Serre, M. L., et al. (2015). Particulate matter exposure, prenatal and postnatal windows of susceptibility, and autism spectrum disorders. Epidemiology 26(1), 30–42.CrossRefPubMedGoogle Scholar
  22. Krumm, N., O’Roak, B. J., Shendure, J., et al. (2014). A de novo convergence of autism genetics and molecular neuroscience. Trends in Neurosciences, 37(2), 95–105.CrossRefPubMedGoogle Scholar
  23. Landrigan, P. J. (2010). What causes autism? Exploring the environmental contribution. Current Opinion in Pediatrics 22(2), 219–225.CrossRefPubMedGoogle Scholar
  24. Leblond, C. S., Heinrich, J., Delorme, R., et al. (2012). Genetic and functional analyses of SHANK2 mutations suggest a multiple hit model of autism spectrum disorders. PLoS Genetics, 8(2), e1002521.CrossRefPubMedPubMedCentralGoogle Scholar
  25. Lord, C., Risi, S., Lambrecht, L., et al. (2000). The autism diagnostic observation schedule-generic: A standard measure of social and communication deficits associated with the spectrum of autism. Journal of Autism and Developmental Disorders, 30(3), 205–223.CrossRefPubMedGoogle Scholar
  26. Lord, C., Rutter, M., & Le Couteur, A. (1994). Autism diagnostic interview-revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. Journal of Autism and Developmental Disorders, 24(5), 659–685.CrossRefPubMedGoogle Scholar
  27. Man, K. K., Tong, H. H., Wong, L. Y., et al. (2015). Exposure to selective serotonin reuptake inhibitors during pregnancy and risk of autism spectrum disorder in children: A systematic review and meta-analysis of observational studies. Neuroscience and Biobehavioral Reviews, 49, 82–89.CrossRefPubMedGoogle Scholar
  28. Mazina, V., et al. (2015a). Interactive effects of copy number variation and maternal infection on autism impairment. Journal of Developmental and Behavioral Pediatrics: JDBP, 36(2), 61–67.CrossRefPubMedPubMedCentralGoogle Scholar
  29. Mazina, V., Gerdts, J., Trinh, S., et al. (2015b). Epigenetics of autism-related impairment: Copy number variation and maternal infection. Journal of Developmental and Behavioral Pediatrics: JDBP, 36(2), 61–67.CrossRefPubMedPubMedCentralGoogle Scholar
  30. Mitchell, A. A., Gilboa, S. M., Werler, M. M., et al. (2011). Medication use during pregnancy, with particular focus on prescription drugs: 1976–2008. American Journal of Obstetrics and Gynecology, 205(51), e1.Google Scholar
  31. O’Roak, B. J., Vives, L., Girirajan, S., et al. (2012). Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature, 485(7397), 246–250.CrossRefPubMedPubMedCentralGoogle Scholar
  32. Rai D, Lee BK, Dalman C, et al. (2013). Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: Population based case-control study. BMJ 346, f2059.CrossRefPubMedPubMedCentralGoogle Scholar
  33. Sanders, S. J., Ercan-Sencicek, A. G., Hus, V., et al. (2011). Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism. Neuron, 70(5), 863–885.CrossRefPubMedPubMedCentralGoogle Scholar
  34. Sanders, S. J., He, X., Willsey, A. J., Ercan-Sencicek, A. G., et al. (2015). Insights into autism spectrum disorder genomic architecture and biology from 71 Risk Loci. Neuron, 87(6), 1215–1233.CrossRefPubMedPubMedCentralGoogle Scholar
  35. Shelton, J. F., Geraghty, E. M., Tancredi, D. J., et al. (2014). Neurodevelopmental disorders and prenatal residential proximity to agricultural pesticides: The CHARGE study. Environmental Health Perspectives, 122(10), 1103–1109.PubMedPubMedCentralGoogle Scholar
  36. Shishido, E., Aleksic, B., & Ozaki, N. (2014). Copy-number variation in the pathogenesis of autism spectrum disorder. Psychiatry and Clinical Neurosciences, 68(2), 85–95.CrossRefPubMedGoogle Scholar
  37. Sorensen, M. J., Gronborg, T. K., Christensen, J., et al. (2013). Antidepressant exposure in pregnancy and risk of autism spectrum disorders. Clinical Epidemiology 15(5), 449–459.CrossRefGoogle Scholar
  38. Stefansson, H., Meyer-Lindenberg, A., Steinberg, S., et al. (2014). CNVs conferring risk of autism or schizophrenia affect cognition in controls. Nature, 505(7483):361.CrossRefPubMedGoogle Scholar
  39. Stessman, H. A., Xiong, B., Coe, B. P., et al. (2017). Targeted sequencing identifies 91 neurodevelopmental-disorder risk genes with autism and developmental-disability biases. Nature Genetics, 49(4), 515–526.CrossRefPubMedPubMedCentralGoogle Scholar
  40. Viktorin, A., Uher, R., Reichenberg, A., et al. (2017). Autism risk following antidepressant medication during pregnancy. Psychological Medicine, 22, 1–10.CrossRefGoogle Scholar
  41. Weiss, L. A., Shen, Y., Korn, J. M., et al. (2008). Association between microdeletion and microduplication at 16p11.2 and autism. The New England Journal of Medicine, 358(7), 667–675.CrossRefPubMedGoogle Scholar
  42. Zimmerberg, B., & Germeyan, S. C. (2015). Effects of neonatal fluoxetine exposure on behavior across development in rats selectively bred for an infantile affective trait. Developmental Psychobiology, 57(2), 141–152.CrossRefPubMedGoogle Scholar
  43. Zufferey, F., Sherr, E. H., Beckmann, N. D., et al. (2012). A 600 kb deletion syndrome at 16p11.2 leads to energy imbalance and neuropsychiatric disorders. Journal of Medical Genetics, 49(10), 660–668.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Sean Ackerman
    • 1
  • Sarah Schoenbrun
    • 2
  • Caitlin Hudac
    • 3
  • Raphael Bernier
    • 4
  1. 1.Department of Psychiatry, Child & Adolescent PsychiatrySSM Dean Medical GroupMadisonUSA
  2. 2.School of MedicineUniversity of WashingtonSeattleUSA
  3. 3.Department of PsychiatryUniversity of WashingtonSeattleUSA
  4. 4.Department of Psychiatry and Center on Human Development and DisabilityUniversity of WashingtonSeattleUSA

Personalised recommendations